We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Cardioneuroablation for Neurocardiogenic Syncope (Ablate-NCS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02009982
Recruitment Status : Completed
First Posted : December 12, 2013
Results First Posted : November 4, 2016
Last Update Posted : November 4, 2016
Biosense Webster, Inc.
Information provided by (Responsible Party):
David B. De Lurgio, Emory University

Brief Summary:

The purpose of this study is to evaluate the effectiveness of cardioneuroablation for the treatment of neurocardiogenic syncope (NCS), also known as "vaso-vagal" syncope. Syncope is a general term for passing out spells and neurocardiogenic syncope is a specific form of passing out spells caused by sudden drops in heart rate or blood pressure. Although the specific mechanisms of NCS are not well understood, it is believed that some people are prone to developing passing out spells in specific situations such as standing up for a long period of time, pain or nausea. In these situations, the body reacts with a paradoxical reflex which leads to a drop in blood pressure and heart rate and causes passing out. Certain types of medications are used to treat NCS including beta-blockers, midodrine and florinef, among others. However, none of these medications are particularly effective at preventing passing out spells and many people continue to have episodes despite trying different medications.

Cardioneuroablation is a new form of treatment for NCS. The term ablation means using a wire to make small electrical burns in the heart. Ablation has been used for many years to treat other electrical disturbances in the heart but the use of ablation to treat NCS is a new application. The goal of cardioneuroablation is to identify areas within the heart which are believed to initiate the reflex which triggers the drop in heart rate and blood pressure that leads to passing out. In preliminary studies, it has been suggested that cardioneuroablation may be significantly more effective than medications at preventing passing out spells for people with NCS.

Hypothesis: Cardioneuroablation of vagal inputs in the left atrium may serve as an effective treatment modality for the prevention of NCS by blunting the initial trigger of the cascade that leads to symptoms and syncope.

Condition or disease Intervention/treatment
Neurocardiogenic Syncope Vasovagal Syncope Procedure: Cardioneuroablation Device: Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 3 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Cardioneuroablation for Neurocardiogenic Syncope
Study Start Date : December 2013
Primary Completion Date : December 2015
Study Completion Date : December 2015

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Fainting
U.S. FDA Resources

Arm Intervention/treatment
Experimental: Cardioneuroablation
Patients in this group will receive the cardioneuroablation procedure using the Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter
Procedure: Cardioneuroablation
Catheter Ablation of Vagal Inputs in Left Atrium
Device: Biosense Webster Navistar ThermoCool Diagnostic/Ablation Deflectable Tip Catheter
This is the device that will be used to perform the Cardioneuroablation procedure
No Intervention: Standard Medical Thearpy
Patients in this group will not receive the cardioneuroablation and will continue to be managed using standard medical therapy

Primary Outcome Measures :
  1. Syncope Recurrence Rate [ Time Frame: 12 Months ]
    The primary endpoint for the study is recurrence of syncope within the 12 month follow-up protocol

Secondary Outcome Measures :
  1. Incidence of Serious Adverse Events [ Time Frame: 12 Months ]
    The secondary endpoint for this study will be the incidence of serious adverse events related to the study procedure within the 12 month follow-up protocol

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Subject is able and willing to sign and date the Patient Consent Form
  • Subject is 18 years of age or older
  • Subject is expected to remain available for the follow-up protocol
  • Subject is willing to comply with the follow-up procedures
  • Subject has medically documented history of neurocardiogenic syncope
  • Subject has had 3 episodes of syncope or presyncope in last 12 months
  • Subject has had a positive tilt table test, defined as the presence of syncope or presyncope associated with abrupt hypotension (SBP < 70 mmHg) or bradycardia (HR < 40 bpm), with or without sublingual nitroglycerin provocation or atropine challenge
  • Subject has been tried on at least one pharmacologic therapy for at least 4 weeks

Exclusion Criteria:

  • Subject has signs and symptoms of an active infection (i.e. fever, elevated white blood cell count, etc.) which has not been treated and/or has not demonstrated improvement in white blood cell count and resolution of fever
  • Subject is pregnant or planning to become pregnant within the study protocol follow-up
  • Subject is enrolled or planning to participate in a concurrent drug and/or device study during the course of this study that would confound study results as determined by the study physician
  • Subject is unwillingly to comply with the randomization procedure
  • Subject has had no syncopal episodes in last six months while on medical therapy
  • Subject has one of the following conditions that is the documented source of syncope: sick sinus syndrome, sinus node or atrioventricular conduction deficiencies, ventricular tachyarrhythmias, pulmonary hypertension, hypertrophic cardiomyopathy, history of transient ischemic attack, seizure disorders, subclavian steal syndrome, or drug-induced syncope
  • Subjects with a myocardial infarction within last six months
  • Subjects with severe heart failure (NYHA class III or IV), previous heart surgery, structural heart disease, or an infiltrative cardiac disease
  • Subject is contraindicated for left-atrial ablation, as determined by enrolling physician

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02009982

United States, Georgia
Emory University
Atlanta, Georgia, United States, 30322
United States, North Carolina
University of North Carolina
Chapel Hill, North Carolina, United States, 27599
Sponsors and Collaborators
David B. De Lurgio
Biosense Webster, Inc.
Principal Investigator: David B DeLurgio, MD Emory University

Responsible Party: David B. De Lurgio, Associate Professor of Medicine, Emory University
ClinicalTrials.gov Identifier: NCT02009982     History of Changes
Other Study ID Numbers: IRB00062061
First Posted: December 12, 2013    Key Record Dates
Results First Posted: November 4, 2016
Last Update Posted: November 4, 2016
Last Verified: September 2016
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No
Plan Description: No due to limited data set and study ending.

Keywords provided by David B. De Lurgio, Emory University:
Cardiac Electrophysiology

Additional relevant MeSH terms:
Syncope, Vasovagal
Consciousness Disorders
Neurobehavioral Manifestations
Neurologic Manifestations
Nervous System Diseases
Signs and Symptoms
Orthostatic Intolerance
Primary Dysautonomias
Autonomic Nervous System Diseases